ProAxsis are delighted to announce that the company will be presenting results from several recent projects at the European Respiratory Society (ERS) annual conference, taking place in virtual format from the 5th-9th September.
Three e-posters will be presented by Dr Darragh McCafferty, the company’s Head of Assay Development, during the ‘BioMarkers for the management of bronchial obstructive diseases’ session on Sunday 5th September between 12.15pm-1.15pm. The titles are as follows:
- Validation of a multiplex assay for measurement of IL-6, IL-8, and TNF-alpha in sputum
- Development of the first protease multiplex immunoassay for active neutrophilic serine protease biomarkers
- An innovative high sensitivity tool for active neutrophil elastase quantification
Dr Timothy Ferguson, the company’s Acting Head of Chemistry, will also present an e-poster at the conference titled ‘Impact of SARS-CoV-2 heat inactivation on active protease biomarkers in sputum sol’ during the ‘Back to infection basics’ session on Monday 6th September between 12.15pm-1.15pm.
ProAxsis look forward to attending this virtual event and hearing about other recent developments in respiratory health and medicine.
Following the conference, copies of the e-posters will be available online at www.proaxsis.com. For further information on how ProAxsis can support with the measurement of inflammatory biomarkers, including active protease biomarkers and cytokines, or for any other queries, please contact email@example.com or phone us on +44 (0) 28 9073 0444.